Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novel Anticancer Agent Trabectedin Meets Primary Endpoint of PFS in PII: Taiho
April 25, 2014
- MTPC Names Masayuki Mitsuka as New President
April 24, 2014
- Yoshindo, Lupin to Establish JV to Develop Etanercept Biosimilar, Start Clinical Trial in FY2014
April 24, 2014
- Ethical Drug Sales Jump 11.0% to Record 240.1 Billion Yen in 2013: Boehringer Japan
April 24, 2014
- Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
- Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
- Metal Objects Found in Voltaren Suppositories in Aichi Pref.: Novartis
April 22, 2014
- Nihon Generic Obtains Teva’s Manufacturing Plant, Eyeing Expansion of Production Capacity
April 22, 2014
- Entry into Japan Biosimilar Market Will Take Time, Says BI Chairman
April 21, 2014
- PIII Trial of Asthma Drug Benralizumab Kicks Off in Japan: Kyowa Kirin
April 21, 2014
- NBI Postpones Launch of Anticancer Drug Giotrif until May 7
April 21, 2014
- Kyowa Kirin, Amgen of US Terminate License Agreement for Mogamulizumab
April 21, 2014
- Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat
April 18, 2014
- Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
- “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
April 18, 2014
- Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
April 18, 2014
- Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
April 17, 2014
- Metal Found in Voltaren Product Again: Novartis
April 17, 2014
- AZ Offers Sales Rep Jobs to over 100 New Graduates in FY2014
April 16, 2014
- Eisai President Naito Awarded Honorary KBE
April 16, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…